HPV-associated Cancer
Conditions
Brief summary
This is an extended follow-up study to follow-up study participants who received 1 booster dose of Gardasil 9 in the HPV vaccine delayed booster trial. This was a prospective, single-arm, open-label, non-randomized, phase IIa trial among 9-11 year-old girls and boys to determine the immunogenicity after a single dose of the nonavalent HPV vaccine (Gardasil 9) over 24 months, with a delayed booster dose at 24 months and an optional booster at 30 months after the first dose. Participants provided blood specimens at 6, 12, 18, 24, and 30 months after the first dose. Serologic geometric mean titers (GMT) of the nine vaccine types (HPV 16/18/ 6/11/31/33/45/52/58) were measured at each time point. One hundred and thirty-three (133) participants received one booster dose at month 24 and elected not to receive the second booster at month 30. For this follow-up study, we anticipate that we will be able to accrue 120 participants from the original study who received just one booster dose. Participants who received one booster dose of Gardasil 9 will be contacted to return to the clinic to provide blood specimens at 48 (±3), 60 (±3), and 72 (±3) months after the priming dose. Serologic geometric mean titers (GMT) of the nine vaccine types (HPV 16/18/ 6/11/31/33/45/52/58) will be measured at each time point.
Interventions
None listed
Sponsors
National Cancer Institute (NCI)
University of California, Los Angeles
University of Arizona
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Study participants who received one booster dose of Gardasil 9 at month 24 and elected not to receive the second booster at month 30 in the original HPV vaccine delayed booster trial * Ability to understand and the willingness to sign a written informed consent document by the legal representative(s) of the participant. * Ability to understand and the willingness to sign a written assent document by the participant.
Exclusion criteria
\- Has received any HPV vaccine dose from an external source at any point during or after participation in the HPV vaccine delayed booster trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The differences in geometric mean titer (GMT) of HPV 16 and HPV18 between 30 vs. 48, 48 vs. 60, and 60 vs. 72 months after the priming dose of Gardasil | 72 months |
Secondary
| Measure | Time frame |
|---|---|
| The differences in geometric mean titer of other HPV types (HPV6/11/31/33/45/52/58) between 30 vs. 48, 48 vs. 60, and 60 vs. 72 months after the priming dose of Gardasil 9 | 72 months |
Countries
United States
Outcome results
None listed